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We recently showed that Magic-F1 (Met-activating genetically improved chimeric factor 1), a human recombinant protein derived
from hepatocyte growth factor/scatter factor (HGF/SF) induces muscle cell hypertrophy but not progenitor cell proliferation, both
in vitro and in vivo. Here, we examined the temporal and spatial expression pattern of Magic-F1 in comparison with Pax3 (paired
box gene 3) transcription factor during embryogenesis. Ranging from 9.5 to 17.5dpc (days post coitum) mouse embryos were
analyzedbyinsituhybridizationusingwholemountsduringearlystagesofdevelopment(9.5–10.5–11.5dpc)andcryostatsections
for later stages (11.5–13.5–15.5–17.5dpc). We found that Magic-F1 is expressed in developing organs and tissues of mesenchymal
origin, where Pax3 signal appears to be downregulated respect to the wt embryos. These data suggest that Magic-F1 could be
responsible of muscular hypertrophy, cooperating with Pax3 signal pathway in skeletal muscle precursor cells.
1.Introduction
M u s c u l a rh y p e r t r o p h yi sc o n t r o l l e db yb o t hm u s c l eg r o w t h
and muscle atrophy. These apparently contrasting biological
processes share key molecules triggering active transcrip-
tional programs to induce skeletal muscles atrophy or hyper-
trophy.
The IGF-1 (insulin-like growth factor-1) pathway aﬀects
both hypertrophy and atrophy, increasing protein synthesis
and inhibiting the expression of transcription factor FOXO
(forkhead box O), respectively. A key molecular player
downstream of IGF-1 receptor is Akt (Abelson leukemia
kinase) that when phosphorylated activates protein synthesis
via mTOR (mammalian target of rapamycin). The two
main actors to negatively control the muscle growth are
myostatin and atrogin-1. Myostatin belongs to the TGF-β
(transforming growth factor beta) family, and it is expressed
and secreted predominantly in skeletal muscle, functioning
as negative regulator of muscle growth. Mice, sheep, cattle,
and humans that present mutations in myostatin gene show
a double-muscling phenotype, characterized by extensive
muscular hypertrophy [1–4]. In vitro myostatin is able to
positively aﬀect the expression of ubiquitin ligases, involved
in muscle atrophy [5]. Interestingly, myostatin treatment
blocks the IGF1-AKT pathway, allowing the increased
expression of atrogin-1, directly involved in muscle atrophy
[6].Amongthemusclegrowthregulators,hepatocytegrowth
factor (HGF/SF) [7–9], initially unveiled as the major
inducers of hepatogenesis, is involved in muscle stem-cell
activation through its tyrosine kinase receptor Met [10–14],
containing a Pax3-binding site. Pax3 is an early transcription
factor involved in embryonic and adult myogenesis, and it is
expressed in the lateral dermomyotome of all somites, where
also is present Met [15]. Transgenic animals generated to
interfere in HGF-Met signaling show abnormality in several
musclesduringembryogenesis[16–18].Moreover,HGF-Met2 Journal of Biomedicine and Biotechnology
pathway is important in muscle regeneration, since, sustains
the proliferation of muscle stem cells after their activation
[19–22]. However, HGF expression is downregulated during
myogenesis in order to allow the satellite cells to exit the cell
cycle, avoiding a delay in the regeneration process [23, 24].
The production of recombinant proteins allows the
great advantage to select a speciﬁc biological eﬀect of a
given protein able to trigger diﬀerent biological processes.
We recently generated transgenic mice expressing an HGF-
related recombinant protein, named Magic factor-1 (Met-
activating genetically improved chimeric factor-1 or Magic-
F1) and expressed exclusively in skeletal muscles [25].
This animal model develops muscular hypertrophy with no
evident side eﬀects or hyperplasia. However, the expression
pattern of the transgene in early embryogenesis is unknown.
The eﬀect of Magic-F1 recombinant protein in skeletal
muscle tissue oﬀers biological advantages over HGF. Magic-
F1 is able to promote myocytes survival and enhance
muscle regeneration and a lack of any mitogenic activity
could allow a potential safe use of the recombinant protein
as therapeutic cytokine for muscle degenerative disorders,
promoting muscle regeneration without the potential risk
of stimulating uncontrolled proliferation. Because of its
selective stimulation of hypertrophy, Magic-F1 is a novel
molecule with potential applicative perspective to counteract
muscle wasting in muscle diseases such as cachexia or
muscular dystrophy.
Here, we evaluate the localization of transgene Magic-
F1 in comparison with Pax3, the earliest myogenic tran-
scription factor, in early and late embryogenesis using
in situ hybridization on whole-mount and cryosections of
transgenic and wt mouse embryos.
2.MaterialsandMethods
2.1. Mouse Embryos and Staging. Embryos for in situ hy-
bridization were dissected from CD1 wt (wild-type) female
mice mated with homozygous Magic-F1 transgenic male
mice (Stem Cell Research Institute, H. S. Raﬀaele, Milan,
Italy). Embryos were generated using timed mating, with the
morning vaginal plug designated as E0.5.
2.2. Genotyping of Magic-F1 Embryos. Magic-F1 is a recom-
binant protein containing two HGF NK2 domains joint
by a linker. The exact amino acidic sequence of Magic-F1
corresponds to residues 1–285 of human HGF (Gene Bank
no.M73239),alinkerwiththesequence(GGGGS)3;residues
30–285 of human HGF, and a poly-histidine tag with the
sequence DDDKHHHHHH. We generated transgenic mice
expressing Magic-F1 construct into a plasmid containing the
1.500-bp (base pair) fragment of the MLC (myosin light
chain) promoter, an 840-bp fragment of SV40 poly(A), and
a 900-bp fragment from the 3  end of the MLC1f/3f gene,
w h i c ha c t sa sa ne n h a n c e ra sp r e v i o u s l yr e p o r t e d[ 25].
To determinate the genotypes of the embryos used in
this study, the yolk sack was removed from each embryo
and was used to prepare genomic DNA (deoxyribonucle-
ic acid), according to a modiﬁed protocol using pro-
teinase K digestion, isopropanol extraction, and ethanol
precipitation. Oligonucleotide primers FW (forward) (5 -
GTGTCAAGGTTCTATTAGGCACTA-3 )a n dREV (reverse)
(5 -GTCCTTTACCAATGATGCAGTTTC-3 ), were used to
amplify a 331bp fragment speciﬁc to Magic-F1.F o re a c h
sample, 20ng of genomic DNA was subjected to a cycle of
predenaturation (94◦C, 3 minutes and 30 seconds), then to
30 cycles of ampliﬁcation consisting of denaturing (94◦C,
15 seconds), annealing 56◦C, 30 seconds) and extension
(72◦C, 45 seconds), followed by two additional extensions
at 72◦C, 7 minutes). The ampliﬁed products were analyzed
by agarose gel electrophoresis in TBE (Tris Borate EDTA)
1X. To conﬁrm that the absence of the band of some
samples was due to the absence of Magic-F1 gene and not
to the absence of DNA, a PCR (polymerase chain reac-
tion) has been performed for GAPDH (glyceraldehyde-
3-phosphate dehydrogenase) gene, using oligonucleotide
primers FW (5 -GGGTGGAGCCAAACGGGT-3 )a n dREV
(5 -GGAGTTGCTGTTGAAGTCGCA). For each sample,
20ng of genomic DNA was subjected to a cycle of predenat-
uration (94◦C, 5 minutes), then to 35 cycles of ampliﬁcation
consisting of denaturing (94◦C, 60 seconds), annealing
(60◦C, 60 seconds) and extension (72◦C, 60 seconds), fol-
lowed by an additional extension at 72◦C, 7 minutes.
2.3. Plasmid and Riboprobe Synthesis. As probes for
hybridization experiments, human Magic-F1 cDNA
(complementary deoxyribonucleic acid) (1759bp) was
ampliﬁed using oligonucleotide primers FW (5 -
ATGTGGGTGACCAACTCCTG-3 )a n dREV (5 -
CTAGTGGTGGTGGTGGTGGTG-3 ). The ampliﬁed pro-
ducts were analyzed by agarose gel electrophoresis in TBE
1X. Magic-F1 bands were excised from the gel, and the
Magic-F1 DNA was extracted (QIAquick Gel Extraction
Kit, QIAgen). Magic-F1 fragments were subcloned into the
pGEM-T Easy Vector System (Promega). Nonradioactive
antisense and sense riboprobes were synthesized by in
vitro transcription using digoxigenin-UTP following the
manufactures instructions (Boehringer Mannheim). Magic-
F1 antisense and sense probes were synthesized using SP6/
T7 RNA (ribonucleic acid) polymerase linearization at a
suitable site: pGEM-T carrying Magic-F1 was digested with
BstXI and Magic-F1 antisense probes were synthesized
using T7 RNA polymerase; Magic-F1 s e n s ep r o b e sw e r e
synthesized using SP6 RNA polymerase after digestion with
ApaI restriction enzyme. The Pax3 antisense and sense
probes were produced by T7 and SP6 RNA polymerase
from pCMV-sport6.1 (Invitrogen) carrying Pax3 cDNA after
proper linearization with EcoRI and BamH1, respectively.
2.4. In Situ Hybridization. Whole-mount in situ hybridiza-
tion on mouse embryos was performed as described [26].
Brieﬂy, embryos were dissected free of all membranes
in phosphate-buﬀered saline (PBS) and ﬁxed in 4%
paraformaldehyde in PBS for 1-2h at RT (Room Tem-
perature) with slow rocking speed. After washing twice in
PTW (PBS, 0.1% Tween-20), embryos were washed with
50% MeOH/PTW and 100% MeOH then stored in 100%
MeOH at −20◦C for less than a month. For hybridization,Journal of Biomedicine and Biotechnology 3
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Figure 1: Magic-F1 transgenic mice. (a) Schematic representation of transgene. (b) Genotyping of 13.5dpc mouse embryos derived by
hemizygous-matched mice; +, − positive and negative control, respectively.
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Figure 2: Expression of Magic-F1 in whole mount embryos. Lateral view of whole-mount in situ hybridization with digoxigenin labeled
antisense Magic-F1 ( a ,b ,d ,e ,f ,g ,h ,a n di )a n ds e n s eMagic-F1 (c) cRNA probes as negative control (ctr-). Speciﬁc hybrids are visualized as
a purple precipitate in all panels except in (a), 9.5dpc and (b) 10.5dpc. (e) Speciﬁc Magic-F1 t r a n s c r i p t sa r ed e t e c t e d( f)i nt h em e s o d e r m a l
cells of the jaw and hyoid bone; in f, tv: telencephalic vesicles, cmt: mesenchymal cephalic tissue, hb: hindbrain, and ba: branchial arches
where muscles are localized as well as around the eyes; a faint expression is also revealed in tail (g) and dorsal (h) somites, while a strong
signal was selected in somites of fore (f
 ) and hind (h
 ) limb buds (i). In embryos hybridized with sense probe (c) background staining has
not been detected as well as on 11.5dpc wild type embryo (wt) hybridized with antisense probes (d).4 Journal of Biomedicine and Biotechnology
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Figure 3: Transcription expression proﬁle of Pax3 (a–c) and Magic-F1 (d–f) on 11.5dpc mouse embryos of hemizygous Magic-F1 (a–f)
and wt (g, h) mice by in situ hybridization. In the sagittal section of transgenic embryo, Pax3 riboprobes reveal a strong signal at the level
of hindbrain (arrowhead in a), neuroepithelium of neural tube (arrow in b), and dorsal somites (c); sagittal section of 11.5dpc embryo
hybridized by Magic-F1 riboprobes (d) shows a similar pattern of Pax3 although no expression was detected at the level of neuroepithelium
of neural tube (arrow in e); speciﬁc transcripts are observed in the cervical dorsal (posterior) root ganglion (arrows in c and f) and somites
(arrowheads in f). In 11.5dpc wt embryo hybridized with Pax3 riboprobes (g), speciﬁc transcripts are detected mostly in the cerebellar
primordium (cerebellar rudiment derived from dorsal part of the alar lamina of the Metencephalon) (arrow) and somites in lumbar
region (arrowhead in g), whereas no signal for Magic-F1 has been detected (h). Immunoﬂuorescence analysis conﬁrmed the presence of
recombinant protein at the level of thoracic (i) and lumbar (j) somites in the transgenic embryos, whereas the signal was faint in the wt
embryos (k), probably referred only to the HGF expression at this stage.
embryos were incubated horizontally at 65◦C overnight in
hybridization mix (50% deionized formamide, 1.3xSSC pH
5, 5mM EDTA pH 8, 50μg/mL Yeast RNA, 0.2% Tween-
20,0.5%CHAPS,100μg/mLHeparin,ddH2O)with1μg/mL
digoxigenin-labeled RNA probes. After in situ hybridization,
the embryos were washed in MABT buﬀer (100mM maleic
acid (Sigma), 150mM NaCl, 0.1% Tween-20, pH 7.5) and
NTMT buﬀer (100mM NaCl, 100mM Tris-HCl pH 9.5,
50mM MgCl2, 0.1% Tween-20) and incubate with staining
solution (4.5μg/m NBT and 3.5μg/mg BCIP). When the
developed color reached the desired extent, embryos were
washed twice with PTW and reﬁxed in 4% HCHO/0.1%
glutaraldehyde/PTW for 2h at RT or 4◦C overnight.
In situ hybridization on mouse cryostat sections was
performedaccordingtoSallyDunwoodie,NIMR.Brieﬂy,the
sections were ﬁxed 4% paraformaldehyde in PBS, digested
withproteinaseKandpostﬁxed.Sectionswereprehybridized
in hybridization solution without probe (50% deionized
formamide, 10x salt, 250μg/mL Yeast RNA, 5x Denhardt’s,
50μg/mL Heparin, 0.1% Tween, ddH2O) in a humid envi-
r o n m e n ta t6 7 ◦C for 2h. After incubation, the prehybridiza-
tion buﬀer was removed and replaced with hybridization
buﬀer containing everything in the prehybridization buﬀer
plus 0.1–1μg/mL labeled cRNA (complementary ribonucleic
acid) riboprobe, denatured for 5min at 80◦C. A coverslip
was placed over the hybridized area and the slides were
then placed in a moist, closed plastic box and hybridized
overnight at 67◦C h. Following hybridization, the coverslips
were washed oﬀ by dipping into 50% formamide, 1xSSC
prewarmed to 67◦C. The tissue was subjected to stringent
washing at 67◦C in 50% formamide, 1xSSC twice for 30min,
followed by two washes in MABT 1X at RT, for 30min
each. Slides were exposed to BMpurple (Roche) for 2h.
Slides were ﬁxed in PFA 4% and washed in PBS, three
times for 5min. Hybridization signals were observed and
photographed using a Nikon microscope. As a negativeJournal of Biomedicine and Biotechnology 5
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Figure 4:ExpressionofPax3 andMagic-F1in13.5dpcmouseembryos.(a)Sagittalsectionof13.5dpcmousehybridizedbyPax3 riboprobes.
A weak signal of Pax3 transcripts have been detected in Magic-F1 transgenic embryos (+/−) at the level of somites in thoracic (b) and
lumbosacral region; in the wild-type age-matched embryo (wt) the signal appeared slightly stronger (c). A faint signal was detected at the
same stage in transgenic embryos hybridized by Magic-F1 antisense riboprobes (d); mainly, the transgenic expression was localized at the
level of somites as shown at higher magniﬁcation in (e). No signal was detected in wild type embryos (wt) by Magic-F1 antisense riboprobes
(f). Arrowheads show somites.
control, specimens were incubated with hybridization buﬀer
containing digoxigenin labeled riboprobes corresponding to
the sense sequence of Magic-F1.
2.5. Immunochemistry. Cryosections placed in a humid,
closed plastic box were ﬁxed for 10min in 4% paraformalde-
hyde in PBS, permeabilized in 0.2% Triton and incubated,
ﬁrst, with a blocking buﬀer (2% donkey serum) contain-
ing 1% blocking solution in PBS for 30min at RT and,
then, a second blocking buﬀer (0.5% mouse serum, 0.5%
goat serum) containing 1% Blocking Solution (Candor-
bioscience GmbH) in PBS for 30min at RT, followed
by incubation with primary antibodies (goat polyclonal
antibody anti-HGF, 1:100 and Mouse monoclonal antibody
anti-Pax3) diluted in 2% BSA (bovine serum albumine) in
PBSovernightat4◦C.SectionswererinsedthreetimesinPBS
followed by a 2h incubation with ﬂuorescein-conjugated
anti-mouse and anti-goat antibodies diluted 1/1500. Slides
were stained with Hoechst dye and mounted in Fluor-
Save. Stained cryosections were observed on an upright
microscope Nikon Vico TE-2000 (Nikon, Japan).
3. Results andDiscussion
3.1. PCR Analysis. PCR analysis of Magic-F1 showed trans-
gene expression in all the embryonic developmental stages
analyzed and an example at stage 13.5dpc is reported in
Figure 1(b). As expected, no signal was detected in the wild-
type embryos due to the high speciﬁcity of the primers able
to discriminate between HGF and the recombinant protein
Magic-F1.
3.2. Whole-Mount In Situ Hybridization. Whole-mount in
situ hybridization was performed to detect Magic-F1 and
Pax3mRNA(messengerribonucleicacid)inembryosatearly
stages of development (9.5, 10.5 and 11.5dpc).
Magic-F1 expression was detected in bone cartilage pri-
mordia, dorsal somites, in tail and limb buds, where Pax3
signal appears to be downregulated respect to the wt
embryos. At 9.5dpc (30 somite stage) and 10.5dpc (40
somite stage) (Figures 2(a) and 2(b)), in situ hybridization
analysis with digoxigenin- (DIG-) labeled antisense probes
showed no expression of Magic-F1 transcript. Magic-F1
transcripts (Figure 2(e)) have been detected from stage of
11.5dpc (58 somite stage) in developing organs and tissues
of mesenchymal origin. Speciﬁcally, positive signal was
observed in mesodermal cells of the jaw, hyoid bone and in
pharyngeal (or brachial) arches from which branchiomeric
muscles are formed. This expression proﬁle conﬁrmed the
musclespeciﬁcityoftheMLC1F(myosinlightchaintype1F)
promoter, regulating Magic-F1 transcription. Furthermore,
speciﬁchybridswerealsodetectedaroundtheeyesatthelevel
of the choroid coat and the sclera, both of mesenchymal ori-
gin,ontheventralanddorsalsideoflimbbuds(Figure 2(d)),
in the dorsal side of some rostral somites (Figure 2(h)), and
in the tail bud (Figure 2(g)). No signal was observed in the
embryos hybridized with the sense riboprobe (Figure 2(i)).
The somites begin to form at the 7.75–8.0dpc, and, after
condensation, they begin to diﬀerentiate into three compart-
ments: the sclerotome, the dermatome, and myotome. At
11.5dpc (58 somite stage), Magic-F1 transcripts have been
detected in all three compartments (sclerotome, dermatome,6 Journal of Biomedicine and Biotechnology
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Figure 5: Expression of Pax3 and Magic-F1 at 15.5dpc. Sagittal section of 15.5dpc mouse hybridized with digoxigenin-labeled antisense
Pax3 riboprobes (a); speciﬁc Pax3 transcripts are localized in cartilage primordium of tail vertebral body, cutaneous muscles (arrow) of
thorax and trunk regions and in mid-cervical region of spinal cord (double arrow) as shown in (b); expression was also localized in cartilage
primordium(arrowhead)ofdorsalpartofshaftregion(c);(d)sagittalsectionof15.5dpcmousehybridizedwithMagic-F1 cRNAprobesand
signal is observed in cartilage primordium of anterior arch of cervical vertebra (arrowheads) and right lobe of thymus gland (arrow); speciﬁc
Magic-F1 transcripts are also localized in cutaneous muscles (arrow) of thorax and trunk regions (e); (f) higher magniﬁcation cartilage
primordium of dorsal part of shaft region of ribs.
and myotome) originating from somites. No signal was
detected in wt embryos at the same stage.
3.3. In Situ Hybridization on Cryostat Sections. In situ hy-
bridization on 10μm-cryostat sections was performed to
localize Magic-F1 and Pax3 transcripts in embryos at later
stages of development (11.5–13.5–15.5–17.5dpc), since the
large size of the samples did not allow a full penetration of
the probes.
At 11.5dpc, transgenic mouse embryos showed Pax3
transcripts expression at the level of hindbrain (Figure 3(a)),
neuroepithelium of neural tube (Figure 3(b)), and dorsal
somites (Figure3(c)). Magic-F1 riboprobes showed a similar
expression pattern (Figure3(d)) reported for Pax3 although
the signal was no detected at the level of neuroepithelium
of neural tube in embryos at the same stage (Figure3(e)).
Speciﬁc transcripts were also observed in the cervical dorsal
(posterior) root ganglion (Figures3(c) and 3(f)) and somites
(Figure3(f)). In addition, at this stage, Pax3 signal can be
observedinwtembryosmainlyinthecerebellarprimordium
and somites in lumbar region (Figure3(f)), whereas no
signal for Magic-F1 has been detected (Figure3(g)).
3.4. Localization of Pax3 and Magi-F1 Proteins and Tran-
scripts. Immunoﬂuorescence analysis was performed to
localize the presence of recombinant protein. In transgenic
embryos at 11.5dpc, MAGIC-F1 was mainly detected at
the level of thoracic (Figure3(i)) and lumbar (Figure3(j))
somites, whereas a faint signal was detected in wt embryos
(Figure3(k)), probably due to the interference with HGF
localizationinthesamearea.At13.5dpc,transgenicembryos
showed a weak signal of Pax3 at the level of somites in
thoracic(Figure 4(a))andlumbosacralregion(Figure 4(b)),
whereasinthewild-typeembryo,thesignalappearedslightlyJournal of Biomedicine and Biotechnology 7
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Figure 6: Expression of Pax3 and Magic-F1 at 17.5dpc. Speciﬁc Pax3 transcripts are localized on sagittal sections of 17.5dpc at the level of
the head (a), in the nucleus pulposus (b) of lumbar intervertebral disc (arrows) of the trunk, and in cartilage primordium (arrowheads) and
wall of spinal cord in midlumbar region (double arrow) as shown in (b) and in cartilage primordium of dorsal part of ribs (c). (d) Magic-F1
signal was observed at the level of cartilage primordium (arrows) of vertebrae.
stronger (Figure 4(c)). A weak signal have been detected in
transgenic embryos hybridized by Magic-F1 antisense ribo-
probes (Figure 4(d)), where Magic-F1 was mainly expressed
at the level of somites (Figure 4(e)), whereas no signal
was detected in wild-type embryos (Figure 4(f)). Speciﬁc
Pax3 transcripts can be detected at later stage (15.5dpc)
(Figure 5(a)) in cartilage primordium of tail vertebral body,
cutaneous muscles of thorax and trunk regions, and in mid-
cervical region of spinal cord (Figure 5(b)). In addition,
at this stage, Pax3 expression demarcated also cartilage
primordium of dorsal part of shaft region (Figure 5(c)). In
sagittal section of 15.5dpc embryo hybridized with Magic-
F1 cRNA probes a strong signal was detected in cartilage pri-
mordium of anterior arch of cervical vertebra and right lobe
ofthymusgland(Figure5(d)).Consistedwiththis,Magic-F1
resulted to be also expressed in cutaneous muscles of thorax
and trunk regions (Figure5(e)) and in primordium of dorsal
part of shaft region of ribs (Figure5(f)). From 17.5dpc
sagittal sections at the level of the head (Figure 6(a)), Pax3
signal was detected in the trunk nucleus pulposus in central
part of lumbar intervertebral disc (Figure 6(b)) and in
cartilage primordium of dorsal part of ribs (Figure 6(c)).
At this stage, Magic-F1 expression was observed at the level
of cartilage primordium of vertebrae (Figure 6(d)). These
data suggest a role of this factor in muscle development
possibly triggering the premature downregulation of Pax3
signal pathway in skeletal muscle precursor cells.
4. Conclusion
Taken together, our data show that Magic-F1 is localized
in speciﬁc expression pattern in the developing muscular
tissues. This could be relevant with the muscle phenotype
previously observed in the transgenic animal model. The
recombinant protein can be considered as a novel member
of Met signaling, since it has been shown to interact with,
andthusinterferingwith,cellmigrationandmyogenesis.Itis
noteworthy that Magic-F1 expression pattern is overlapping
with Pax3, however, limited only in developing muscular
tissue, where exerts its myogenic potential. In fact, Pax3 is
able to activate Myf5 (Myogenic factor 5) myogenic master
gene [25], leading to the formation of skeletal muscle. In
addition, Pax3 orchestrates FGF (ﬁbroblast growth factor)
cascade [27], targeting directly Fgfr4 (ﬁbroblast growth fac-
tor receptor 4) and Sprouty1 known to inhibit FGF pathway.
Magic-F1 may interfere with the balance between stem cell
self-renewal and cell diﬀerentiation in developing muscles,
mainly operated by Pax3 and Pax7 (paired box gene 7) [28].
It is unlikely that it is directly involved in stem-cell renewal;
however, competing with HGF, the natural Met ligand could
be move the balance towards muscle diﬀerentiation.
Further studies are necessary to elucidate Magic-F1
speciﬁc role in cell speciﬁcation and diﬀerentiation during
embryogenesis.
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